News & Updates

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

09/26/2022

Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical benefit observed with the combination of etigilimab and nivolumab, including in PD-L1 negative or low subjects Excerpt from the Press Release: LONDON and MOUNTAIN VIEW, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Mereo BioPharma…

Read More

In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

09/26/2022

50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution without worsening of fibrosis, three to five times the placebo rate (15%) 50mg (41%) and 28mg (29%) groups demonstrated fibrosis improvement AND resolution of NASH,…

Read More

Join Christopher Kata in San Diego for the “IN”novation Mixer Networking Event on September 28th!

09/25/2022

We’re extending this special invitation to our “IN”novation Mixer event, hosted by TrialStat Solutions, Avance Clinical, Science Media and Life Sciences Marketplace on Wednesday, September 28th, starting at 5 pm PT at The Winery Restaurant and Wine Bar, located in the UTC Westfield Plaza at 4301 La Jolla Village Dr Ste 2040, San Diego, CA 92122. Please join Christopher Kata, and a select…

Read More

Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

09/23/2022

EBT-101 is an in vivo CRISPR-based therapeutic designed to remove HIV proviral DNA from affected cell reservoirs First-in-human study will evaluate the safety and efficacy of EBT-101 in participants who chronically suppress HIV with daily antiretroviral therapy EBT-101 has been well tolerated to-date and the trial is proceeding as planned Excerpt from the Press Release:…

Read More

BioJiva Reports Results of Pilot Phase 2 Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

09/23/2022

Signals of Clinical Benefit Detected in Small Phase 2 Study, Suggesting Potential to Show Statistically Significant Therapeutic Benefit in Larger, Targeted Trial Consistent Benefit vs. Placebo in Primary and Secondary Endpoints, With Greater Benefit Witnessed in More Severe Patients Excerpt from the Press Release: LOS ALTOS, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) — BioJiva, a…

Read More

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

09/23/2022

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone Excerpt from the Press Release: LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced…

Read More

Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis

09/22/2022

Interim results demonstrate statistically significant improvement compared to placebo in hemoglobin levels from baseline to week 12 Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–A prespecified interim analysis of the ALPHA Phase III trial evaluating danicopan (ALXN2040), an investigational, oral factor D inhibitor, as an add-on to C5 inhibitor therapy ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab)…

Read More

RevBio Receives Approval from the U.K.’s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial

09/22/2022

RevBio Receives Approval to Start a Clinical Trial in the United Kingdom to Study a Modified Formulation of its Bone Adhesive Biomaterial for Implant Dentistry Excerpt from the Press Release: LOWELL, Mass.–(BUSINESS WIRE)–RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a…

Read More

Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer Institute

09/22/2022

Excerpt from the Press Release: CAMBRIDGE, Mass., Sept. 16, 2022 /PRNewswire/ — Marengo Therapeutics, a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the right T cell subsets to fight cancer, today announced it is advancing its lead TCR activator, STAR0602, into the clinic following clearance of its…

Read More

Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from the G-MAB Library

09/21/2022

Excerpt from the Press Release: SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento G-MAB™ library with neutralizing activity against SARS-CoV-2 in vitro and in vivo in Scientific Reports, a Nature portfolio journal. About Sorrento…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives